Benzinga | Mar 26, 2021 08:34AM EDT

180 Life Sciences Reports Availability Of Broadcast 'Controlling Inflammation to Stop Disease'; Press Release Notes Founding Team Members Of Co. 'recognized pioneers of research and development in anti-inflammatory therapeutics'

NetworkNewsAudio -- 180 Life Sciences Corp. (NASDAQ:ATNF) announces the availability of a broadcast titled, "Controlling Inflammation to Stop Disease."

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/VFpw9

Ongoing research and clinical trials for anti-tumor necrosis factor (anti-TNF) antibodies in autoimmune inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis and Crohn's disease seem likely to only add to market growth and expansion as new anti-TNF uses are found. The wild card is that new findings implicate inflammation in a variety of other disorders with high unmet medical need. Research is ongoing and clinical trials are in progress with more planned for later this year. With any success, market forecasts many have to be adjusted substantially higher.

The founding team members at 180 Life Sciences Corp. (NASDAQ:ATNF) are the recognized pioneers of research and development in anti-inflammatory therapeutics. 180 Life Sciences is a clinical-stage biotechnology company that brings together the expertise of world-renowned scientists to develop and test novel treatments for inflammation and is currently working in both preclinical and clinical studies. By leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University, the company is leading new research into solving the complexities of inflammation to answer vast unmet medical needs.